News from Abroad: Antibodies in the European Patent Office

McDonnell Boehnen Hulbert & Berghoff LLP
Contact

The following article was reprinted with permission from J A Kemp.

The European Patent Office (EPO) continues to grant many patents relating to antibodies, and in doing so applies the same patentability criteria as to other inventions.  However, some commentators have suggested that antibodies are regarded as a special case by the EPO when evaluating inventive step / obviousness.  It is implied that the EPO sets a higher patentability threshold for inventions in this field as compared to, for example, small molecule therapeutics.

This perception likely reflects no more than the crowded nature of the antibody field, which has matured rapidly in recent years.  As a result, EPO Examiners are able to make a large (and increasing) number of assumptions regarding the background knowledge of the skilled person.  For example, in the absence of evidence to the contrary, the EPO considers it to be routine to raise an antibody to a known target.  The EPO also considers it to be routine to optimise certain characteristics of an antibody, such as affinity or immunogenicity.

Although it is not unique to the field, the approach of the EPO can present significant challenges to applicants seeking to pursue claims to antibodies, particularly antibodies to known targets.  We have set out below our suggestions for how grant of antibody claims at the EPO might nonetheless be achieved in different factual scenarios.  We have also set out the types of supporting evidence that may be required in each case.  Figure 1 provided at the end of this briefing summarises the suggestions in the form of a decision tree, which may help to guide you to the most appropriate strategy at different stages in an antibody development project.

Scenarios likely to Result in Broad claims

Broad antibody claims typically arise from two basic scenarios.  In the first scenario, the target is a newly-identified molecule, or is a molecule to which it has previously proven difficult to raise an antibody.  In such cases, the antibody may be defined solely in terms of the target bound.  For example:

"An antibody which specifically binds to "

In the second scenario, the target is found to have a previously unappreciated role in a disease.  That is, the target is found to be associated with a new medical use.  In such cases, the antibody may be defined by reference to the target bound and the new medical use.  For example:

"An antibody which specifically binds to for use in a method of treating ".

These two basic scenarios are discussed in more detail below.

Newly-Identified or Difficult Target

The extensive mapping of genomes and proteomes means that truly "new" targets are increasingly rare.  However, an applicant who identifies, for example, a new polypeptide (potentially including new mutant forms of a known polypeptide) can expect to obtain broad claims to any antibody that specifically binds to the new polypeptide.  It is not typically necessary to provide evidence that an antibody has actually been produced if the target is susceptible to routine methods of antibody production.

An applicant who develops a method allowing an antibody to be raised for a known target which was not susceptible to routine methods can also expect to obtain broad claims.  The EPO effectively views such a target as a special category of new target -- it is "newly available" for antibody production.  Inventions of this type are though increasingly rare.  Methods of antibody production have developed such that few targets are not now susceptible to them, and overcoming technical difficulties is frequently seen as routine.  If the EPO can be persuaded otherwise for a particular case, the patent application will need to include clear evidence that an antibody to the target has indeed been raised, as well as sufficient information to allow this to be repeated.

For antibodies to such newly-identified targets or difficult targets, medical use claims may be allowable even without direct evidence of a clinically-relevant functional effect.

New Medical Use

Where a known target molecule is found to have a previously unappreciated role in a disease, it may be possible to obtain claims directed to any antibody that specifically binds to the target for use in a particular method of treatment.  In a typical scenario of this type, the target has a known association with one disease, but is subsequently found to have a role in a different (new) disease that was not previously appreciated.  Under such circumstances the claims will be limited to an antibody for use in a method of treating the new disease, but will cover any anti-target antibody for the said use.

It will be necessary to establish that the new medical use is not obvious from any previous disclosure regarding the target or existing antibodies that bind to it.  It will also be necessary to establish that it is at least plausible that an antibody binding to the target will have a therapeutic effect.  At present this is a relatively low threshold at the EPO and in vitro functional data will likely be sufficient, particularly if it derives from a disease model or other assay relevant to the indication.  In vivo data from animal models is helpful but not required.  It is not normally expected that a patent application will include in vivo data from human clinical trials.

Similar considerations may apply if it was previously thought that the only antibodies that could be produced to a target were pharmaceutically irrelevant (for example due to low affinity), but it is subsequently found that they have a therapeutic effect1.  In such cases a claim to a pharmaceutical composition comprising any antibody specific for the target may be possible.

Scenarios which may Result in Narrower Claims

It is unlikely that broad antibody claims will be available if both the target and associated medical uses are known.  However, grant of narrower claims may still be possible.  Such claims will likely need to incorporate limitations from either or both of the following categories.

New or Improved Characteristic of an Antibody

Limitations to specific functional characteristics of the antibody, such as a required level of affinity or a down-stream functional effect, likely also with at least some structural (sequence) characteristics.

New Development of a Known Medical Use

Limitations to specific aspects of the medical use, such as a particular patient group or a dosing/administration regime.

Both categories are discussed in more detail in the following section.  The categories are not mutually exclusive, and claims including both should be pursued wherever possible as part of a comprehensive filing strategy (see additional comments on filing strategy in the separate section below).  However, in our experience, at any given stage in development a particular antibody project is likely to favour limitations from one category over the other.

New or Improved Characteristic of an Antibody

Examples of the types of functional characteristic that applicants may seek to rely upon are described in more detail below.  These examples should not be viewed as exhaustive or mutually exclusive.  In practice a combination of these and other characteristics may well provide the best route to allowable claims.

Irrespective of the characteristic(s) relied upon, pursuit of this approach will likely require that applicants have provided a significant amount of structural information (primary amino acid sequences) in the patent application.  Whether a particular antibody is claimed directly or is recited as a reference antibody, the EPO often insists that structural detail be provided at a level at least sufficient to define the target binding region of an antibody.  It may alternatively be possible to meet these requirements by reference to a biological deposit of, for example, a hybridoma, provided the deposit is made in accordance with the Budapest Treaty.

Historically, the EPO has accepted structural definitions of antibodies which refer only to one or two CDR sequences.  However, EPO Examiners are likely now to insist upon all six CDRs as a minimum requirement, unless data is available to show that any characteristic relied upon is achieved with fewer CDRs.  There is though an increasing appreciation of the relevance of framework regions to target binding, and so there is a trend towards requiring that the heavy and light chain variable region sequences be recited in full.  In some cases it may even be necessary to specify the isotype of the constant region if this is relevant to the characteristic(s) relied upon.

By contrast to its approach for small molecule therapeutics, the EPO does not in general consider that a unique structure can confer inventive step on an antibody to a known target.  Thus, whilst an antibody comprising a unique primary sequence will be considered to be novel, structural non-obviousness arguments are unlikely to be accepted even when both variable region sequences are recited in full.

This means that applicants will generally be unable to rely upon, for example, the determination of unique CDR and framework sequences to provide an inventive step.

Instead, the EPO has developed a requirement that a new antibody to a known target must demonstrate "an unexpected effect" relative to pre-existing antibodies to the same target2 in order for inventive step to be acknowledged.  It will therefore generally be necessary to demonstrate that the antibody as claimed possesses a functional characteristic (or combination of characteristics) which could not reasonably have been predicted from the prior art.

Ideally, at least some direct experimental evidence of the characteristic(s) relied upon will be provided in the patent application, for at least one exemplary antibody.

Under some circumstances it may be possible to rely upon supplementary data filed later, but there must be a connection to the characteristic(s) shown in the application.  The characteristic(s) relied upon must be at least plausible at the filing date3.

This test has been applied very strictly by the EPO on at least one occasion.  In a specific case4 the Board of Appeal held that a particular effect relied upon by an applicant to support inventive step could not be derived from the patent application itself, even though an arguably related effect was explicitly demonstrated in the Examples.  Accordingly the effect relied upon was considered to have been demonstrated only after the filing date of the application, and was not taken into account when assessing inventive step.

If the EPO is persuaded that "an unexpected effect" is present and plausible, the breadth of claim that is allowed will depend upon the circumstances of each case -- in particular the state of the prior art and the data available.

At the narrowest end of the spectrum, it may be necessary to limit the claims to the specific sequences of an antibody which has been shown to possess the unexpected effect.  For example:

"An antibody which binds specifically to and which comprises a VH region comprising SEQ ID NO: x and a VL region comprising SEQ ID NO: y."

At the opposite end of the spectrum, and more rarely, it may be possible to claim a general class of antibodies which achieves the said effect, defined solely in functional terms. For example:

"An antibody which binds specifically to and which has ."

It will be necessary for the application to include sufficient information such that the skilled person can generate further examples of an antibody which meets the functional definition.  The identification in the patent application of a specific, structurally-defined antibody which can be used as a reference / control in a screening method is usually acceptable.  However, it is not unusual for an Examiner to require that the claim also include some structural information about the claimed antibody or the reference antibody.  As such, allowable claims may be a hybrid of the two types shown above.  For example:

"An antibody which binds specifically to and which has , wherein the antibody competes for binding to with an antibody which comprises a VH region comprising SEQ ID NO: x and a VL region comprising SEQ ID NO: y."

Examples of Possible New Characteristics

As mentioned above, the following examples should not be viewed as exhaustive or mutually exclusive.  In practice a combination of these and other characteristics may well provide the best route to allowable claims.  The goal is to establish that there is a technical effect or characteristic (or multiple such effects or characteristics) which can be shown to have been unexpected based on the relevant prior art.

Affinity

The EPO considers the generation of an antibody with nanomolar affinity to be achievable by routine methods for the vast majority of targets.  Whilst there may be exceptions for particularly difficult targets, high affinity alone is now unlikely to be sufficient to establish an inventive step.  However, high affinity in combination with another advantageous characteristic is nonetheless likely to be helpful.

Specificity

The EPO tends to view high specificity for target to be an inherent characteristic of all antibodies and so an increase in specificity alone is unlikely to be sufficient to establish an inventive step.  However, an increase in specificity which gives rise to an unexpected technical advantage, or which was previously thought to be difficult to achieve, may be enough.  For example if a new antibody is able to distinguish between closely-related targets to a greater extent than was previously possible.

Epitope

An antibody which can bind to an epitope in a target that was previously unrecognised and/or previously considered to be inaccessible is likely to be viewed as inventive.  Under certain circumstances this may even be seen as a sub-category of the "Newly-identified or difficult target" scenario described above.  If binding to the particular epitope also provides a functional advantage (e.g. enhanced specificity) this is likely to be helpful.

Manufacturability

Routine optimisation for improved solubility etc is unlikely to be viewed as inventive.  However, there may be exceptions if the nature or position of any substitutions, and the subsequent effect, can be shown to have been unexpected.  For example, if a surprising increase in affinity or specificity occurs.

Immunogenicity

Humanisation of antibodies to reduce anti-isotypic or idiotypic responses is now largely viewed as routine, as is the production of fully human antibodies.  However, as with manufacturability there may be exceptions if the nature or position of any substitutions, and the subsequent effect, can be shown to have been unexpected.

The Board of Appeal has held in one case5 that particular point mutations to introduce human sequences in the framework regions of a specific mouse antibody were sufficient to acknowledge inventive step for that antibody.  The evidence in that case persuaded the Board that the skilled person could not reasonably have expected that those specific mutations would reduce immunogenicity without significantly reducing affinity.

Down-Stream Functional Effects

Any improvement in down-stream function is likely to be helpful when seeking to establish an inventive step.  However, adaptations of an antibody to enhance down-stream functions such as ADCC are unlikely to be viewed as inventive where they rely upon known phenomena such as altered glycosylation of Fc regions.

New Development of a Known Medical Use

It seems it is becoming ever more challenging to persuade the EPO that a new or improved characteristic of an antibody is enough alone to establish inventive step.  However, in our experience antibody inventions are treated no differently to other therapeutics when assessing further developments of a known medical use, in which a new and unexpected technical effect can be demonstrated.

The scope of claim that may be available via this route will depend upon the data produced, since it will be necessary to show that the effect relied upon is achieved across substantially the whole scope claimed.  This may require limitation to an antibody defined by a complete structural definition (including constant regions), if the EPO do not accept that the effect relied upon applies more generally, for example to all antibodies possessing the same six CDRs.

Ideally the data showing the effect should be present in the patent application.  However, data generated post-filing may be used to supplement arguments later in prosecution, provided the effect relied upon is plausible at the filing date6.

Bearing this in mind, we consider that inventions of this type are generally in one of two categories:

Combinations

(Bispecific Molecules/Combination or Co-Administration with other Therapeutics/Conjugates)

Any form of therapy which combines an antibody with another functionality may give rise to allowable claims.  Examples include a combination with another binding functionality in the same molecule (a bispecific molecule), a combination with another effector functionality in the same molecule (a drug/toxin conjugate), or the co-administration of the antibody with another therapeutic (combination or co-administration), or any combination of these types.  In each case, as with any combination of known therapeutics, it will be necessary to establish that the combination results in a technical effect (typically an advantage) which was not obvious from the prior art (e.g. synergistic increase in efficacy).  It will likely be necessary to include experimental evidence of the technical effect in the patent application.

Treatment Methodologies

(Patient Group/Dose or Formulation/Administration Route or Regime)

The Enlarged Board of Appeal of the EPO has established7 that claims to second/further medical uses of a substance may be based not only on the treatment of a different disease, but also on the treatment of the same disease by a method which differs for example in the dosage, formulation, administration regime, group of subjects or route of administration.  In each case, as with any known therapeutic, it will be necessary to establish that the difference gives rise to a technical effect (typically an advantage) which was not obvious from the prior art (e.g. surprisingly enhanced efficacy for topical versus parenteral administration).  It will likely be necessary to include experimental evidence of the technical effect in the patent application.

New Types of Antibody

An invention which relates to a new type of antibody may give rise to broad claims which are not limited to a specific antibody or target.  Examples of possible inventions in this category could include a novel and inventive arrangement of the binding domains (a new antibody "format"), a novel and inventive effector region (such as a modified Fc domain), or an entirely different class of antibody molecule isolated from a newly-discovered species.

For inventions of this type, the assumptions that the EPO would otherwise make regarding production and optimisation of known antibody types should largely be negated.  The EPO should treat such inventions in the same way as any other technology, since normal considerations of novelty, inventive step and sufficiency of disclosure should apply.  As such the assessment of each case will depend upon its merits.

Comprehensive Filing Strategy

A typical antibody development project will pass through different stages, and at each stage it may correspond more closely to one or the other of the scenarios outlined above.  This briefing is intended to provide some suggestions as to how patentable claims may be achieved in each scenario.  These suggestions are also summarised in Figure 1.

However, the scenarios that are described are not mutually exclusive.  As with any therapeutic invention, a comprehensive filing strategy should seek to explore all of the available options for patent protection throughout the lifespan of the project and beyond.  For example, an initial broad filing to a new medical indication should be followed with multiple narrower filings to antibodies with improved characteristics and/or developments of the treatment methodology.

Figure 1

Figure 1


1 Board of Appeal decision T601/05: claims to a pharmaceutical composition comprising human anti-TNFα antibodies were found to be inventive. At the time only low affinity human antibodies to the target could be generated, and it was thought that these were not suitable for pharmaceutical use.
2 Board of Appeal decision T735/00
3 Board of Appeal decision T1329/04
4 Board of Appeal decision T2637/11
5 Board of Appeal decision T0067/11
6 Board of Appeal decision T1329/04
7 Enlarged Board of Appeal decision G2/08

This article was reprinted with permission from J A Kemp.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.